Oxcarbazepine Dosing for Vestibular Paroxysmia
For vestibular paroxysmia, start oxcarbazepine at 150 mg twice daily (300 mg/day total) and titrate by 150 mg every 2-3 days until reaching a target dose of 600-900 mg/day, with most patients achieving symptom control at 300-600 mg/day total.
Initial Dosing Strategy
The evidence strongly supports a low-dose approach for vestibular paroxysmia, which differs substantially from epilepsy dosing:
- Starting dose: 150 mg twice daily (300 mg/day total) 1
- Alternative starting dose: 100 mg three times daily (300 mg/day total) 1
- Studies specifically in vestibular paroxysmia used 300 mg twice daily as the standard dose 2, 3
This is notably lower than FDA-approved epilepsy dosing, which recommends starting at 600 mg/day 4. The lower doses are appropriate because vestibular paroxysmia responds to sodium channel blockade at substantially lower concentrations than seizure disorders.
Titration Schedule
Gradual escalation approach:
- Increase by 150 mg every 2-3 days until symptom control is achieved 5
- Target maintenance dose: 600-900 mg/day (300-450 mg twice daily)
- Maximum effective dose for vestibular paroxysmia: typically 600 mg/day 2, 3
Important distinction: While epilepsy patients may require up to 2,400 mg/day 4, vestibular paroxysmia patients typically achieve complete symptom control at much lower doses. The literature consistently shows efficacy at 300-600 mg/day total 1, 6.
Special Population Considerations
Elderly Patients
Reduce initial dose by 50% in elderly patients due to age-related pharmacokinetic changes:
- Elderly patients (60-82 years) show 30-60% higher plasma concentrations of the active metabolite (MHD) compared to younger patients 4
- This is primarily due to age-related reduction in creatinine clearance 4
- Starting dose for elderly: 150 mg/day (75 mg twice daily), then titrate more slowly
- Monitor closely for CNS side effects (dizziness, drowsiness, ataxia)
Renal Impairment
Critical dosing adjustments required:
For creatinine clearance <30 mL/min 4:
- Start at half the usual dose: 150 mg/day (75 mg twice daily)
- The elimination half-life doubles from 9 hours to 19 hours 7
- Plasma concentrations increase 2-2.5 times in severe renal impairment 7
- Titrate more slowly than in patients with normal renal function
- Maximum dose should be reduced proportionally
For moderate renal impairment (creatinine clearance 10-30 mL/min):
- Reduce maximum target dose by 50% 7
For mild renal impairment (creatinine clearance >30 mL/min):
- No dose adjustment needed 7
Hepatic Impairment
No dose adjustment required for mild-to-moderate hepatic impairment 4. Oxcarbazepine is metabolized by cytosolic enzymes rather than hepatic cytochrome P450 enzymes, making it safer in liver disease.
Practical Titration Algorithm
Week 1:
- Days 1-3: 150 mg twice daily (300 mg/day)
- Assess response and tolerability
Week 2:
- If incomplete response: increase to 225 mg twice daily (450 mg/day)
- If good response: maintain current dose
Week 3:
- If still incomplete response: increase to 300 mg twice daily (600 mg/day)
- Most patients achieve complete control by this dose 2, 3
Maintenance:
- Continue effective dose for at least 12 weeks to assess full therapeutic benefit 2, 3
- Response typically occurs within 2-4 weeks
Augmentation Strategy
Consider adding betahistine mesilate if oxcarbazepine alone provides incomplete control:
- Betahistine 18 mg twice daily shows superior efficacy compared to 12 mg twice daily 2
- The combination of oxcarbazepine 300 mg + betahistine 18 mg twice daily achieved higher response rates and greater symptom reduction 2
- This combination has lower side effect rates than carbamazepine-based regimens 3
Common Pitfalls to Avoid
Over-dosing: Do not use epilepsy dosing protocols (600-2,400 mg/day). Vestibular paroxysmia responds to much lower doses.
Too-rapid titration: Rapid escalation increases CNS side effects (dizziness, drowsiness) without improving efficacy.
Ignoring renal function: Always check creatinine clearance before initiating therapy. Failure to adjust for renal impairment leads to toxicity.
Premature discontinuation: Allow at least 12 weeks at therapeutic dose before declaring treatment failure 2, 3.
Missing drug interactions: Oxcarbazepine induces CYP3A4 and can reduce effectiveness of oral contraceptives 4. Counsel patients accordingly.
Monitoring Requirements
- Baseline: Serum sodium, creatinine clearance, liver function tests
- Follow-up: Serum sodium at 2-4 weeks (risk of hyponatremia, though uncommon) 5
- No routine therapeutic drug monitoring required for vestibular paroxysmia (unlike epilepsy)
Alternative Agents
If oxcarbazepine is not tolerated or contraindicated: